The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

- Recognized for its industry leading opti-ox™ technology that produces cultivated meat with speed and efficiency, Meatable leads industry on quest to solve protein shortages and food insecurity ...

bit.bio is a synthetic biology company that uses its cell identity coding platform to reprogram induced pluripotent stem cells to create any human cell type. With its cell identity coding platform, ...

Tony Oosterveen (left) is a Principal Scientist at bit.bio (Cambridge, UK), a company pioneering the generation of physiologically relevant human cell types from induced pluripotent stem cells (iPSCs) ...

BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...